undamentalytics Newsletter
Sign in

Bolt Biotherapeutics, Inc. income statement

In fiscal 2025, Bolt Biotherapeutics, Inc. reported revenue of $7.7m, up 0.1% on the year before, operating income of −$36.1m (a -469.3% margin) and net income of −$33.4m, or −$17.85 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0168885
Research and development40767362572922
General and administrative9182323181412
Operating income−49−93−90−76−73−36−31
Income before tax————−63−33—
Income tax000000—
Net income−61−99−88−69−63−33−29
Diluted EPS−$1.93−$2.97−$2.36−$1.83−$33.06−$17.85−$16.38
Diluted shares (average)2m2m2m2m2m2m2m
EBITDA−49−92−89−74−71−35−30

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BOLT vs TRDABOLT vs OCGNBOLT vs RANI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bolt Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bolt Biotherapeutics, Inc.